Westedt M L, Dijkmans B A, Hermans J
Service de Rhumatologie, Hôpital Universitaire, Leiden, Pays Bas.
Rev Rhum Ed Fr. 1994 Oct;61(9):591-7.
Thirty-eight patients with active rheumatoid arthritis (RA) were entered in an open randomized 24-week study comparing azathioprine (AZA; initial daily dose 1 mg/kg) with methotrexate (MTX; initial weekly dose 7.5 mg). The patients had previously been treated with antimalarials, gold salts and/or D-penicillamine. The groups were well balanced in baseline characteristics. There were three premature withdrawals in each group, all of which were due to toxicity. The present study did not show any significant differences between AZA and MTX in ability to reduce activity in RA after 24 weeks of treatment.
38例活动性类风湿关节炎（RA）患者进入一项为期24周的开放随机研究，比较硫唑嘌呤（AZA；初始日剂量1mg/kg）与甲氨蝶呤（MTX；初始周剂量7.5mg）。这些患者此前曾接受抗疟药、金盐和/或青霉胺治疗。两组在基线特征方面均衡良好。每组均有3例提前退出，均因毒性反应。本研究未显示在治疗24周后，AZA和MTX在降低RA活动度的能力上有任何显著差异。
